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We read with great interest an article by 
Li et al. [1] which reviewed the cardiovascular 
complications in COVID-19 patients. The authors 
discuss many disease entities, including cardiac 
injury, myocarditis, acute coronary syndrome, 
heart failure, or sudden cardiac arrest. However, 
it is worth adding to this catalog cardiac tampon-
ade, which is a pathological condition that directly 
threatens a patient’s life. It consists in filling the 
pericardial cavity with a fluid that has the nature 
of an exudate or effusion, thus hindering filling the 
atria. Tamponade may arise because of infarction, 
trauma, mediastinal tumors and many other clinical 
conditions [2, 3].
Since December 2019, the world has been 
struggling with the pandemic of infections of 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), causing coronavirus disease 2019 
(COVID-19). There is an increased recognition of 
cardiac involvement in patients with COVID-19 as 
it confers a worse prognosis. The most common 
cardiac complications include acute myocardial in-
jury, arrhythmias, acute myocarditis and severe left 
ventricular dysfunction. However, several authors 
including Asif et al. [4] present a case of COVID-19- 
-associated acute viral pericarditis complicated by 
large pericardial effusion and cardiac tamponade. 
Also, Hakmi et al. [5] showed that cardiac tam-
ponade with concomitant biventricular failure can 
develop in COVID-19 patients.
As mentioned previously, cardiac tamponade 
is a life-threatening condition and, in the event 
of intensification of symptoms, requires urgent 
intervention in the form of decompression of the 
pericardial sac. However, in order not to delay 
the tamponade diagnosis procedure, especially 
in patients with suspected/confirmed COVID-19, 
when medical staff wears full personal protective 
equipment for aerosol generating procedures (PPE 
AGP), ultrasonography may be helpful [6, 7]. For 
this purpose, the Focus Assessment Transthoracic 
in Emergency (FATE) protocol can be used. 
The aim of the aforementioned is to perform 
basic echocardiographic projections — sub-sternal, 
apical, parasternal and bilateral pleural projections 
(in the middle axillary lines in the costal arch). 
The ultrasonographic images acquired in this way 
allows confirmation or exclusion of cardiac tam-
ponade, and, with its presence under ultrasound 
control, it is also possible to drain it.
In conclusion, cardiac tamponade, which can 
also be associated with COVID-19 infection, is 
a therapeutic challenge requiring immediate confir-
mation and implementation of invasive treatment.
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